/
Oncology
Pancreatic Ductal Adenocarcinoma
122
Pipeline Programs↗
98
Active Trials↗
65
Companies Involved↗
Pancreatic Ductal Adenocarcinoma is a highly competitive landscape with 122 programs across 65 companies. The most active players are Boehringer Ingelheim, Eli Lilly, Perspective Therapeutics. 16 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical13
Phase 140
Phase 253
Phase 316
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
91 of 111 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 111 classified programs, each share of the total. Modality classified for 92% of 122 pipeline programs.
Analysis
Trial Status
154
clinical trials
Recruiting55 · 36%
Completed27 · 18%
Not yet recruiting22 · 14%
Active, not recruiting20 · 13%
Terminated16 · 10%
Unknown status5 · 3%
Other9 · 6%
Clinical Trials
Trial Activity
154 trials
An Open Labelled Phase III Adjuvant Trial of Disease-free Survival in Patients With Resected Pancreatic Ductal Adenocarcinoma Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
Recruiting·—·Phase 3·NCT05314998·394 enrolled
Page 1 of 11
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)